MKI67 and central nervous system cancer: In our study, IDHm, 1p19q codeletion (or ATRX protein expression), percentage of Ki67-positive cells and histological grade were associated with survival of patients with recurrent grades II–III glioma from diagnosis, but not from bevacizumab initiation.